Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in support of the ongoing BLA review SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clini ...

New virtual agent capabilities reduce customer effort, prevent repeat contacts, and give service leaders confidence to scale automationWith 43% of consumers saying chatbots fail to resolve their issues, Zoom Virtual Agent 3.0 can help organizations close that gap SAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Today Zoom Communications, Inc. (NASDAQ: ZM) unveiled Zoom Virtual Agent 3.0 (ZVA), the next evolution in agentic automation. ZVA introduces a new execution architecture and expanded AI capabiliti ...

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced its award-winning photographers, editors and operations staff will capture stunning imagery from the Milano Cortina 2026 Paralympic Winter Games. As the Official Photographic Agency of the International Paralympic Committee (IPC), Getty Images will deploy a team of 30 photograp ...

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep. This new relationship supports OneMedNet’s continued focus on expanding its base of subscri ...

Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi ...

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, ...

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9 ...

Holds of Over 9,000 ETH-based Cryptocurrencies and Staked 2,600 ETH as of February 23, 2026SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we” or the “Company”), a company engaged in the provision of altcoin mining products, and delivery of Web3 infrastructure services via the strategic acquisition and holding of Ethereum-based cryptocurrencies, and operation of a Proof-of-Stake (“PoS”) cryptocurrency staking platform, today provided an update on its Ethereum (“ETH”) acc ...

Core Insights - Treasure Global Inc. reported significant financial progress in Q2 FY2026, with revenue reaching USD 1.08 million, up from USD 0.30 million in Q2 FY2025, driven by growth in gift-card transactions on the ZCITY platform [9] - The company experienced a net loss of USD 3.11 million, compared to a loss of USD 0.23 million in the same quarter last year, although this was partially offset by favorable fair-value adjustments [9] - Cash and cash equivalents increased to USD 5.45 million from USD 0.24 million as of June 30, 2025, supported by financing activities [9] Financial Highlights - Revenue for Q2 FY2026 was USD 1.08 million, a significant increase from USD 0.30 million in Q2 FY2025 [9] - Net loss was USD 3.11 million, compared to USD 0.23 million in Q2 FY2025 [9] - Loss per share improved to USD (3.47) from USD (11.32) in Q2 FY2025 [9] - Cash and cash equivalents rose to USD 5.45 million from USD 0.24 million as of June 30, 2025 [9] Management Commentary - The CEO highlighted the company's progress in strengthening its financial position and advancing technology initiatives [3] - Emphasis was placed on enhancing digital commerce capabilities and expanding higher-value opportunities within the ecosystem [3] - The company is focused on sustainable growth and scaling operations across Southeast Asia [3] Operational Updates - Treasure Global is enhancing its digital commerce ecosystem, particularly through the ZCITY platform [4] - The company is improving product development processes and operational efficiency while expanding merchant partnerships [5] - These efforts aim to diversify revenue streams and strengthen the company's position in Southeast Asia's digital economy [5] Business Outlook - The company plans to continue developing the OXI Wallet initiative, which supports its long-term fintech strategy [6] - OXI Wallet is expected to expand digital asset capabilities and create new revenue opportunities [6] - The company remains committed to optimizing its business model and enhancing operational efficiency [7]

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has received acceptance from the National Medical Products Administration of China for the New Drug Application of ruxolitinib phosphate cream for treating mild to moderate atopic dermatitis, which is expected to accelerate the marketing approval process [1][4]. Group 1: Product Development and Approval - Ruxolitinib phosphate cream has been approved for marketing by the NMPA for the treatment of vitiligo and is now expanding its indications to atopic dermatitis, marking a significant milestone in its therapeutic applications [2]. - The NDA for ruxolitinib phosphate cream has been included in the Priority Review List, reducing the review timeline from 200 days to 130 days, which is anticipated to expedite the product's availability to patients [4]. Group 2: Clinical Trial Results - The product demonstrated robust efficacy in a Phase III clinical trial, achieving a significantly higher proportion of subjects reaching an Investigator's Global Assessment score of 0 or 1 compared to placebo (63.0% vs 9.2%, P < 0.001) [6]. - For the secondary endpoint, 78.0% of subjects treated with ruxolitinib phosphate cream achieved at least a 75% improvement in the Eczema Area and Severity Index score compared to 15.4% in the placebo group (P < 0.001) [6]. Group 3: Market Potential and Strategic Positioning - Atopic dermatitis affects over 54 million patients in China, with mild to moderate cases accounting for 98% of these, indicating a substantial market opportunity for ruxolitinib phosphate cream [5]. - Dermavon is developing a comprehensive "treatment + care" solution for atopic dermatitis, which includes ruxolitinib phosphate cream and other therapeutic options, enhancing its leadership in dermatology [6][7]. - The acceptance of the NDA for atopic dermatitis is expected to strengthen Dermavon's strategic positioning in skin treatments and create synergies with its existing product portfolio, potentially enhancing market competitiveness [8].